Pluristem Granted Patents in Australia and New Zealand for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications

HAIFA, Israel, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, announced today that it has been granted a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications. The patent, titled "Adherent cells from placenta and use of same in disease treatment" has been issued in Australia, Patent No. 2010322808, and in New Zealand, Patent No. 600651.

The patents' claims include the use of the population of placental cells in the treatment of muscle trauma, muscle defect, neuropathic pain, peripheral nerve injury, and neurodegenerative diseases.

"These patents, which cover multiple indications and bring the Company's total to 32 granted patents, are timely, as we've demonstrated Pluristem's ability to use its technology platform to develop distinct cell therapy product lines for the potential treatment of different conditions. We continue to evaluate additional indications for PLX-PAD and PLX-RAD, our first two cell therapy products," stated Pluristem CEO Zami Aberman.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, hematological disorders, radiation damage, and ischemia. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

In addition to its strong intellectual property position, Pluristem has Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com , the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements in this press release when we discuss the potential of our product candidates to treat different conditions or that we continue to evaluate additional indications for PLX-PAD and PLX-RAD. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Pluristem Therapeutics Inc.: Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 144

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 121

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 90

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 96

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 28

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Trifork Group Launches 2025 Share-Based Incentive Program

Updated Category News Views 333

Trifork's Innovative Share-Based Incentive Program The Trifork Group AG has taken a significant step towards enhancing employee satisfaction and retention with the introduction of its Share-Based Incentive Program for 2025. This strategic decision supports Trifork’s ongoing commitment to fostering a motivated workforce and aligns with the company’s vision for growth...

Continue Reading
China's Agricultural Modernization: Dezhou's Vital Role

Updated Category News Views 40

Modern Farming Revolution in Dezhou Fifteen years ago, farming technology in Dezhou was a distant dream; today, it's a shining reality. Picture this: Song Zhijie, a veteran farmer, reflecting on a dusty 1997 summer harvest. Now, he sits in air-conditioned cabins, operating state-of-the-art machinery, basking in the efficiency that modern technology has granted. Dezhou, a...

Continue Reading
Exploring the Growth of the Cultured Wheat Market: 2024-2034

Updated Category News Views 142

Exploring the Growth of the Cultured Wheat Market The cultured wheat market is set for remarkable growth, with projections indicating an increase from USD 704.1 million in 2024 to USD 1,273.0 million by 2034. This growth translates to a solid compound annual growth rate (CAGR) of 6.1% over the decade. The rising demand for cultured wheat is driven by several factors,...

Continue Reading
Transforming Urban Mobility: Hikvision's AIoT Innovations

Updated Category News Views 292

Hikvision showcased its game-changing AIoT innovations at the ITS World Congress, zeroing in on making urban mobility safer, smarter, and greener. Their booth was abuzz with tech that’s not just flashy; it’s a serious play aimed at reshaping how we think about transport. The emphasis here? A commitment to road safety that's palpable, with cutting-edge solutions that...

Continue Reading
Avem Health Partners Welcomes Military Veterans to Board of Directors

Updated Category News Views 90

Enhancing Leadership at Avem Health Partners Avem Health Partners, a well-respected hospital management company based in Oklahoma City, is excited to announce the recent appointments of Keith Walker and Barbara Holcomb to its Board of Directors. This strategic decision aims to infuse the organization with a wealth of experience from both military and corporate...

Continue Reading